ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL911
CHEMBL911
Compound Name ZOLPIDEM
ChEMBL Synonyms SL 80.0750-23N | ZOLPIDEM | EDLUAR | SL-80.0750-23N | AMBIEN CR | ZOLPIDEM TARTRATE | TOVALT ODT | ZOLPIMIST | STILNOCT | INTERMEZZO | Ambien
Max Phase 4 (Approved)
Trade Names TOVALT ODT | ZOLPIDEM TARTRATE | EDLUAR | INTERMEZZO | Ambien | STILNOCT | AMBIEN CR | ZOLPIMIST
Molecular Formula C19H21N3O

Additional synonyms for CHEMBL911 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CN(C)C(=O)Cc1c(nc2ccc(C)cn12)c3ccc(C)cc3
Standard InChI InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4 ...
Download InChI
Standard InChI Key ZAFYATHCZYHLPB-UHFFFAOYSA-N

Sources

  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL911

Molecule Features

CHEMBL911 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:Y Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator GABA A receptor alpha-1/beta-1/gamma-2 FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Depressive DisorderD003866EFO:0003761unipolar depression3ClinicalTrials
Substance-Related DisordersD019966EFO:0003890drug dependence2ClinicalTrials
Attention Deficit Disorder with HyperactivityD001289EFO:0003888attention deficit hyperactivity disorder3ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma1ClinicalTrials
DementiaD003704HP:0000726dementia3ClinicalTrials
AnxietyD001007EFO:0005230anxiety3ClinicalTrials
ObesityD009765EFO:0001073obesity1ClinicalTrials
SchizophreniaD012559EFO:0000692schizophrenia3ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
Marijuana AbuseD002189EFO:0004218marijuana dependence1ClinicalTrials
Sleep Initiation and Maintenance DisordersD007319EFO:0004698insomnia4ClinicalTrials
DailyMed
DailyMed

Clinical Data

ClinicalTrials.gov ZOLPIDEM
The Cochrane Collaboration ZOLPIDEM

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL911. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL4552 Peripheral-type benzodiazepine receptor Rattus norvegicus 1.000
CHEMBL5742 Translocator protein Homo sapiens 1.000
CHEMBL2431 Serine/threonine-protein kinase AKT2 Homo sapiens 0.336
CHEMBL1962 GABA receptor alpha-1 subunit Homo sapiens 0.317
CHEMBL2524 Alpha-galactosidase A Homo sapiens 0.302
CHEMBL215 Arachidonate 5-lipoxygenase Homo sapiens 0.292
CHEMBL1901 Cholecystokinin A receptor Homo sapiens 0.265
CHEMBL5162 Neuropeptide S receptor Homo sapiens 0.260
CHEMBL260 MAP kinase p38 alpha Homo sapiens 0.208



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL4552 Peripheral-type benzodiazepine receptor Rattus norvegicus 1.000
CHEMBL5742 Translocator protein Homo sapiens 0.999
CHEMBL4869 Prion protein Homo sapiens 0.821
CHEMBL1293226 Lysine-specific demethylase 4D-like Homo sapiens 0.718
CHEMBL2608 Lysosomal alpha-glucosidase Homo sapiens 0.538
CHEMBL2524 Alpha-galactosidase A Homo sapiens 0.521
CHEMBL215 Arachidonate 5-lipoxygenase Homo sapiens 0.381
CHEMBL4159 Endoplasmic reticulum-associated amyloid beta-peptide-binding protein Homo sapiens 0.281
CHEMBL5162 Neuropeptide S receptor Homo sapiens 0.238

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
307.4 307.1685 3.25 3 37.61 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
3 0 0 4 0 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 6.77 3.09 3.03 3 23 0.74

Structural Alerts

There are no structural alerts for CHEMBL911

Compound Cross References

ATC N - NERVOUS SYSTEM
N05 - PSYCHOLEPTICS
N05C - HYPNOTICS AND SEDATIVES
N05CF - Benzodiazepine related drugs
N05CF02 - zolpidem

ChemSpider ChemSpider:ZAFYATHCZYHLPB-UHFFFAOYSA-N
DailyMed zolpidem tartrate
PubChem SID: 144205024 SID: 170465242 SID: 26749064
Wikipedia Zolpidem

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL911



ACToR 82626-48-0
BindingDB 26266
Brenda 145090 146004
ChEBI 10125
ChemicalBook CB83360349
DrugBank DB00425
DrugCentral 2870
eMolecules 596284
EPA CompTox Dashboard DTXSID7045946
FDA SRS 7K383OQI23
Guide to Pharmacology 4348 4362
Human Metabolome Database HMDB0005023
IBM Patent System 2028844833ECEBDD0874C071220BA248
KEGG Ligand C07219
LINCS LSM-5560
Nikkaji J33.161I
PharmGKB PA451976
PubChem 5732
PubChem: Thomson Pharma 14874110
SureChEMBL SCHEMBL80516
ZINC ZINC000000003876

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/ZAFYATHCZYHLPB-UHFFFAOYSA-N spacer
spacer